GlassScriptPhysician profile
Michael L Chin
NPI 1083680466
$619.99
in general payments reported to CMS, 2019-2025
9 companies · $212 in 2025
The $212 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.93 · 2020: $64.26 · 2021: $13.89 · 2023: $175 · 2024: $61.42 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $447.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $109.94 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Janssen Pharmaceuticals, INC | $107.00 | 2019-2023 | Xarelto |
| Angiodynamics, INC. | $101.61 | 2025 | Auryon Laser System 100-120 Vac |
| Amgen INC. | $78.15 | 2020-2021 | |
| Lilly USA, LLC | $61.42 | 2024 | Mounjaro |
| Amarin Pharma, INC. | $61.13 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.26 | 2023 | Jardiance |
| Integra Lifesciences Corporation | $38.06 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Abbott Laboratories | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.